1 |
Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance [J]. Kidney Int, 2015, 87(4): 698-711.
|
2 |
Heher EC, Goes NB, Spitzer TR, et al. Kidney disease associated with plasma cell dyscrasias [J]. Blood, 2010, 116(9): 1397-1404.
|
3 |
Pozzi C, D′Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors [J]. Am J Kidney Dis, 2003, 42(6): 1154-1163.
|
4 |
Hasegawa H. Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology [J]. Int J Cell Biol, 2013, 2013: 604867.
|
5 |
Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy [J]. Clin J Am Soc Nephrol, 2006, 1(6): 1342-1350.
|
6 |
Sirac C, Bridoux F, Carrion C et al. Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome [J]. Blood, 2006, 108(3): 536-543.
|
7 |
Teng J, Turbat-Herrera EA, Herrera GA. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes [J]. Kidney Int, 2014, 86(4): 738-746.
|
8 |
Sirac C, Bridoux F. Mesangial cells as amyloid factory: a unique contribution of animal models [J]. Kidney Int, 2014, 86(4): 669-671.
|
9 |
Yadav P, Leung N, Sanders PW, et al. The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease [J]. Kidney Int, 2015, 87(4): 692-697.
|
10 |
Parry HM, Pratt G, Hutchison CA. Monoclonal gammopathy of undetermined significance: an update for nephrologists [J]. Adv Chronic Kidney Dis, 2012, 19(5): 291-296.
|
11 |
Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study [J]. Lancet, 2010, 375(9727): 1721-1728.
|
12 |
Chang SH, Luo S, O′Brian KK, et al. Association between metformin use and transformation of monoclonal gammopathy of undetermined significance to multiple myeloma in U.S. veterans with diabetes mellitus: a population-based cohort study [J]. Lancet Haematol, 2015, 2(1): e30-e36.
|
13 |
Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance (MGRS) [J]. Blood, 2013, 122(22): 3583-3590.
|
14 |
Leung N, Bridoux F, Hutchison CA, et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant [J]. Blood, 2012, 120(22): 4292-4295.
|
15 |
Sicard A, Karras A, Goujon JM, et al. Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist [J]. Nephrol Dial Transplant, 2014, 29(10): 1894-1902.
|
16 |
Melmed GM, Fenves AZ, Stone MJ. Urinary findings in renal light chain-derived amyloidosis and light chain deposition disease [J]. Clin Lymphoma Myeloma, 2009, 9(3): 234-238.
|
17 |
McTaggart MP, Lindsay J, Kearney EM. Replacing urine protein electrophoresis with serum free light chain analysis as a first-line test for detecting plasma cell disorders offers increased diagnostic accuracy and potential health benefit to patients [J]. Am J Clin Pathol, 2013, 140(6): 890-897.
|
18 |
Jenner E. Serum free light chains in clinical laboratory diagnostics [J]. Clin Chim Acta, 2014, 427: 15-20.
|
19 |
Colombat M, Holifanjaniaina S, Guillonneau F, et al. Mass spectrometry-based proteomic analysis: a good diagnostic tool for cystic lung light chain deposition disease [J]. Am J Respir Crit Care Med, 2013, 188(3): 404-405.
|
20 |
Gerth J, Busch M, Ott U, et al. Evolution of light chain deposition disease over 8 years [J]. Clin Nephrol, 2009, 72(5): 397-401.
|
21 |
Gharwan H, Truica CI. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure [J]. Med Oncol, 2012, 29(2): 1197-1201.
|
22 |
Hutchison CA, Cockwell P, Stringer S. Early reduction of serum-Free light chains associates with renal recovery in myeloma kidney [J]. J Am Soc Nephrol, 2011, 22(6): 1129-1136.
|
23 |
Weber N, Mollee P, Augustson B, et al. Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group [J]. Intern Med J, 2015, 45(4): 371-382.
|
24 |
Lorenz EC, Gertz MA, Fervenza FC, et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease [J]. Nephrol Dial Transplant, 2008, 23(6): 2052-2057.
|
25 |
Jimenez-Zepeda VH. Light chain deposition disease: novel biological insights and treatment advances [J]. Int J Lab Hematol, 2012, 34(4): 347-355.
|
26 |
Royer B, Arnulf B, Martinez F, et al. High dose chemotherapy in light chain or light and heavy chain deposition disease [J]. Kidney Int, 2004, 65(2): 642-648.
|
27 |
Telio D, Shepherd J, Forrest D, et al. High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease [J]. Bone Marrow Transplant, 2012, 47(3): 453-455.
|
28 |
Kastritis E, Migkou M, Gavriatopoulou M, et al. Treatment of light chain deposition disease with bortezomib and dexamethasone[J]. Haematologica, 2009, 94(2): 300-302.
|
29 |
Gharwan H, Truica CI. Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure [J]. Med Oncol, 2012, 29(2): 1197-1201.
|
30 |
Petrakis I, Stylianou K, Mavroeidi V, et al. Biopsy-proven resolution of renal light-chain deposition disease after autologous stem cell transplantation [J]. Nephrol Dial Transplant, 2010, 25(6): 2020-2023.
|
31 |
Tovar N, Cibeira MT, Rosiñol L, et al. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease [J]. Eur J Haematol, 2012, 89(4): 340-344.
|
32 |
Tsakiris DJ, Stel VS, Finne P, et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study [J]. Nephrol Dial Transplant, 2010, 25(4): 1200-1206.
|
33 |
Cohen C, Royer B, Javaugue V, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease [J]. Kidney Int, 2015, doi: 10.1038/ki.2015.201. [Epub ahead of print].
|